Statin drug interactions: the chart, the myopathy risk, and which statins avoid the problem

Pravastatin, rosuvastatin and pitavastatin are the three that avoid CYP3A4 metabolism, so they sidestep the largest and most common category of statin interaction entirely. Pravastatin is the cleanest on paper because it undergoes very little metabolism of any kind. Rosuvastatin is nearly as clean for CYP purposes but is a substrate of the OATP1B1 and BCRP transporters, so cyclosporine, gemfibrozil and some antiretrovirals still raise its concentration and its labeling carries dose caps in those combinations.

That is why the practical question at the point of care is rarely "which statin is safest" in the abstract. It is "which statin is safest with the specific drug I am about to add". A patient starting a two-week course of itraconazole needs a different answer from a transplant recipient on long-term cyclosporine, even though both are CYP3A4 problems on the surface.

Clarithromycin is a strong CYP3A4 inhibitor, so combining it with simvastatin or lovastatin raises statin concentrations substantially and is one of the best documented causes of drug-induced rhabdomyolysis in outpatient practice. The labeling for those statins reflects this directly. Atorvastatin sits in between and typically carries a dose cap rather than a prohibition.

There are three usual ways out, and which one applies is a clinical decision rather than a rule. Substituting azithromycin, which does not inhibit CYP3A4 meaningfully, removes the interaction if the infection allows it. Holding the CYP3A4 statin for the seven to ten days of the antibiotic course carries essentially no cardiovascular cost and is widely described. Or the patient can be moved to pravastatin or rosuvastatin permanently, which is often worth doing anyway in someone who gets recurrent respiratory infections.

The clinical picture usually starts as symmetrical proximal muscle pain, tenderness or weakness, often in the thighs and shoulders, sometimes with dark urine when it progresses. Creatine kinase elevation is the laboratory marker, and rhabdomyolysis with acute kidney injury is the severe end of the spectrum. Risk rises with statin dose, with the number of interacting drugs, with advanced age, with hypothyroidism, and with reduced renal or hepatic function.

What makes this worth screening for rather than waiting for is the timing. Symptoms often appear within days to a few weeks of the interacting drug being added, at which point the patient is more likely to attribute the aching to the infection they are being treated for than to the statin they have taken uneventfully for years. Asking directly about new muscle symptoms when an interacting drug is started catches more of these than waiting for a complaint.

Grapefruit is the real one, and it is specific. Furanocoumarins irreversibly inactivate intestinal CYP3A4, which matters for statins with high first pass metabolism, so simvastatin and lovastatin are affected and pravastatin and rosuvastatin essentially are not. Because the enzyme has to be resynthesized, spacing the juice away from the dose does not fix it. Seville oranges and pomelo behave the same way; ordinary oranges do not.

Among supplements, red yeast rice is the one worth asking about explicitly, because it contains monacolin K, which is chemically the same as lovastatin. A patient taking it alongside a prescribed statin is effectively double dosing, and the same CYP3A4 interactions apply. Coenzyme Q10 is commonly taken with statins and is not an interaction in the pharmacokinetic sense. St John's wort works the other way, inducing CYP3A4 and lowering concentrations of the statins that depend on it.

The statin interaction problem is not a knowledge gap. Every prescriber knows clarithromycin and simvastatin do not belong together. The problem is that the statin was started three years ago by someone else, appears halfway down a list of eleven medications, and the antibiotic is being prescribed at the end of a long session for a patient whose chief complaint is a cough.

Prescriber.io takes the full regimen, flags the statin interaction with the mechanism stated plainly and the source cited, and returns it alongside contraindication and allergy checks, renal and hepatic dose considerations, and guideline-based alternatives, in one card rather than several separate lookups. It is decision-support for licensed US clinicians and it never prescribes. You review the flag, verify against the current labeling, apply judgment, and sign.